Lotfi Hadad, MD
Medical Oncology · Evansville, INNPI 1952362477
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Johnson & Johnson at 25.5% of the total. Reporting peaked in 2021 at $463 and has fallen 91.5% since, to $40 in 2025. That places this record below the midpoint for medical oncology clinicians in IN, where the typical reported total is $2,472.
Across 78 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$318
- Genentech USA, Inc.$145
- Dexcom, Inc.$138
- AstraZeneca$84
- GSK$81
- Novo Nordisk$59
- plus $423 from 20 others
What the payments were for
- Food & beverage$1,248100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 23 | $318 |
| Genentech USA, Inc. | 9 | $145 |
| Dexcom, Inc. | 9 | $138 |
| AstraZeneca(2 entities) | 4 | $84 |
| GSK | 5 | $81 |
| Novo Nordisk | 4 | $59 |
| Boehringer Ingelheim | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Bristol Myers Squibb | 2 | $32 |
| Gilead | 1 | $26 |
| Pfizer | 1 | $22 |
| Seagen Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| AbbVie | 1 | $20 |
| Sanofi | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Incyte Corporation | 1 | $13 |
| Theratechnologies Inc. | 1 | $13 |
| Neos Therapeutics, LP | 1 | $13 |
| EMD Serono, Inc. | 1 | $12 |
How this compares
$1,248 in reported general payments places this provider in the 35th percentile of 67 medical oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GattexTeduglutide | 13 | $600,134 |
| PromactaEltrombopag Olamine | 13 | $148,627 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $406 |
| Anastrozole | 13 | $258 |
| Omeprazole | 20 | $223 |
| Escitalopram Oxalate | 12 | $120 |
| Cyclobenzaprine Hcl | 13 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $35 | $600,13413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 67 medical oncology providers in Indiana.
Other medical oncology in Evansville
- Costantine AlbanyLafayette$212K
- Sunil BabuFort Wayne$166K
- Natraj AmmakkanavarIndianapolis$129K
- Rafat AnsariMishawaka$90K
- Bert OneilIndianapolis$89K
- Pablo BedanoIndianapolis$52K
- Gregory SmithIndianapolis$46K
- Ashwin VasudevamurthyIndianapolis$44K
- Eduardo BraunWestville$39K
- Daniel SonnenburgIndianapolis$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.